RenovoRx, Inc.
About
Issuer
- Entity type
- Corporation
- Jurisdiction
- Delaware
- Sector
- Biotech
- Headquarters
- Mountain View, CA
- Street
- 2570 W El Camino Real, Suite 320
- Zip
- 94040
Offering
- Total offering
- $10M
- Amount sold
- $10M
- First sale
- Mar 20, 2026
- Min investment
- $10k
- Securities
- Equity
- Federal exemption
- Rule 506(b)
- Investors so far
- 16
How this filing compares
Ranked #11 of 47 Biotech filings in April 2026 by offering amount.
Median Biotech filing in April 2026: $3M. This offering is 3.3× the median.
Other California filings this week: A-Star Fund III, LP, Artie Technologies Inc., BAY HILLS CAPITAL PARTNERS VI-A, L.P., BAY HILLS CAPITAL PARTNERS VI, L.P., Cityview Real Estate Partners VIII, LP
Leadership
Shaun R. Bagai — Executive Officer (also: Director)
Mark Voll — Executive Officer
Leesa Gentry — Executive Officer
Ramtin Agah — Executive Officer
Laurence J. Marton — Director
Una S. Ryan — Director
Kirsten Angela Macfarlane — Director
Robert J. Spiegel — Director
Filing details
RenovoRx, Inc. filed a Form D with the SEC on April 9, 2026.